載入中
NYSEHealthcareMedical - Pharmaceuticals
最新資料
US$0.118
−US$0.0009 · -0.76%
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.
前收盤價
US$0.118
−US$0.0009 · -0.76%
盤中時間採用ET。市場資料可能有所延遲。
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.
日內區間
目前US$0.118
52週區間
目前US$0.118
盤中時間採用ET。市場資料可能有所延遲。
Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse portfolio includes conventional small molecule drugs, advanced biologics (which are derived from biological processes), and specialized chimeric antigen receptor (CAR-T) cell therapies. The company was established in August 1933 and maintains its corporate headquarters in Princeton, New Jersey.
日內區間
目前US$0.118
52週區間
目前US$0.118
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 481.94億 USD | 483億 USD | 450.06億 USD | 461.59億 USD | 463.85億 USD |
| 銷貨成本 | 164.36億 USD | 208.68億 USD | 106.93億 USD | 101.37億 USD | 99.4億 USD |
| 毛利 | 317.58億 USD | 274.32億 USD | 343.13億 USD | 360.22億 USD | 364.45億 USD |
| 研究與開發 | 94.92億 USD | 111.59億 USD | 92.99億 USD | 95.09億 USD | 101.95億 USD |
| 銷售、一般及管理費用 | 71.49億 USD | 78.65億 USD | 77.72億 USD | 78.14億 USD | 76.9億 USD |
| 營業費用 | 166.41億 USD | 177.74億 USD | 261.18億 USD | 269.18億 USD | 279.08億 USD |
| 利息收入 | 5.86億 USD | — | — | — | — |
| 利息支出 | 18.91億 USD | 19.47億 USD | 11.66億 USD | 12.32億 USD | 13.34億 USD |
| 折舊和攤銷 | 41.21億 USD | 96億 USD | 97.6億 USD | 102.76億 USD | 106.86億 USD |
| 營業利益 | 151.17億 USD | 96.58億 USD | 81.95億 USD | 91.04億 USD | 85.37億 USD |
| 淨利 | 70.54億 USD | −89.48億 USD | 80.25億 USD | 63.27億 USD | 69.94億 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
